Polyamide Compound Mitochondrial DNA Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for mitochondrial genetic diseases, such as MELAS, are primarily symptomatic and lack a fundamental treatment approach, with challenges in delivering therapeutic agents across mitochondrial and cellular membranes to target specific mutations like the A3243G mutation, and existing methods like PNA therapy have shown limited effectiveness in living cells.
Innovation Solution
A polyamide compound that selectively binds to wild-type mitochondrial DNA, promoting its replication and shifting the heteroplasmy ratio, thereby treating mitochondrial genetic diseases caused by various mutations, including A3243G, by selectively binding to specific nucleotide pairs and using residues like γ-aminobutyric acid and N-methylpyrrole to facilitate membrane penetration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PNA therapy is used to inhibit replication of mutant mtDNA, then selective inhibition of mutant DNA replication is achieved, but effectiveness in living cells is limited due to membrane penetration challenges
Solution Approach 1:
The patent uses polyamide compounds as intermediary molecules that can penetrate mitochondrial and cellular membranes more effectively than PNA, while still achieving selective binding to mutant mtDNA sequences. The polyamide acts as a mediator that overcomes the membrane barrier problem while maintaining the selective inhibition function.
Solution Approach 2:
The invention changes the chemical parameters of the therapeutic agent from PNA to polyamide compounds with specific amino acid compositions and structural characteristics that enable membrane penetration. The polyamide compounds have modified physical-chemical properties including amphipathic structures and basic amino acid residues that facilitate crossing lipid membranes while retaining sequence-specific binding capability.
2Ease of operation
If conventional symptomatic treatment is used for mitochondrial diseases, then clinical symptoms are managed, but fundamental cause (gene mutations) is not addressed
Solution Approach 1:
Instead of treating symptoms as conventional approaches do, the patent inverts the treatment strategy by directly targeting the genetic cause (mutant mtDNA) to prevent disease manifestation. The polyamide compounds selectively bind to mutant mtDNA sequences, inhibiting their replication and allowing wild-type mtDNA to dominate, thereby addressing the root cause rather than symptoms.
3Productivity
If polyamide compound is designed to bind wild-type mtDNA, then replication of wild-type mtDNA is promoted, but selective binding to specific nucleotide pairs must be achieved
Solution Approach 1:
The polyamide compounds are designed with specific local qualities - particular amino acid residues at specific positions in the sequence that confer binding specificity to certain nucleotide pairs (A/T, G/C). The patent describes how specific residues like γ-aminobutyric acid, β-alanine, N-methylpyrrole, and N-methylimidazole are positioned to recognize and bind to complementary DNA base pairs, enabling selective promotion of wild-type mtDNA replication while excluding mutant sequences.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polyamide compound effectively increases the replication of wild-type mtDNA, allowing for the treatment of mitochondrial genetic diseases by shifting the heteroplasmy ratio, thereby addressing the fundamental cause of the disease and improving energy production in cells.
Implementation Method 1
A polyamide compound that selectively binds to wild-type mitochondrial DNA, promoting its replication and shifting the heteroplasmy ratio
Implementation Method 2
using residues like γ-aminobutyric acid and N-methylpyrrole to facilitate membrane penetration
Data Source
AI summary
The object of the present invention is to provide a fundamental therapy to mitochondrial genetic diseases caused by mutation of the mitochondrial (mt)DNA, and a pharmaceutical composition used for the same.The object can be solved by a polyamide compound binding to a target double-stranded mtDNA comprising A/T pair consisting of first A of the following sense-stranded DNA and the corresponding T, A/T pair consisting of 8th A of the following sense-stranded DNA and the corresponding T, G/C pair consisting of 9th G of the following sense-stranded DNA and the corresponding C, G/C pair consisting of 14th G of the following sense-stranded DNA and the corresponding C, T/A pair consisting of 15th T of the following sense-stranded DNA and the corresponding A, or the like, in the double-stranded DNA consisting of the sense-stranded DNA having base sequence of 5′-ATGGCAGAGCCCGGTAATCGCATAA-3′ (SEQ ID NO: 1) and the antisense-stranded DNA having base sequence of 5′-TTATGCGATTACCGGGCTCTGCCAT-3′ (SEQ ID NO: 2).